SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$9.54
+1.81%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$9.59
From 52W high−62.07%
Volume4.17M
Market cap$858.87M
P/E (TTM)—
P/S (TTM)3.0x
Div yield—
Key dataNov 6, 2026
Open
$9.59
From 52W high
−62.07%
Volume
4.17M
Market cap
$858.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.6x
P/E (TTM)
—
RSI (14)
27.2
MomentumView details →
1D Return
+1.81%
YTD Return
−53.76%
SummaryUpdated Sep 1, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Waltham, Massachusetts. The company went public in March 2016 and has evolved from a research-focused organization into a commercial-stage company with two FDA-approved products launched in 2024. Syndax specializes in developing novel therapies for cancer treatment, with particular expertise in targeting specific protein interactions and immune system pathways that drive tumor growth and resistance to treatment.
Similar companies
Latest newsMore news →
Syndax Pharmaceuticals Inc announced that 19 abstracts on Revuforj (revumenib) and Niktimvo (axatilimab-csfr) were accepted for presentation at ASH 2026, including seven oral presentations.3d agoSyndax Pharmaceuticals Inc reported a third-quarter loss of $0.55 per share, compared with a loss of $0.70 per share a year earlier.5d agoSyndax Pharmaceuticals Inc reported third-quarter 2026 total revenue of $83.3 million, up 82% year over year, including Revuforj net revenue of $60.7 million and Niktimvo net revenue of $67.4 million.5d ago